Mental Health. Clarity. Balance.
Anxiety

2027 Trials Target Severe Depression and PTSD with Psilocybin

Opti Therapeutics launches 2027 trials of psilocybin for severe MDD and PTSD, enrolling 200 adults in a phase 2b study.

2027 Trials Target Severe Depression and PTSD with Psilocybin

Why 2027 Marks a Turning Point

Opti Therapeutics will launch a phase 2b study of OPTI-101 for major depressive disorder and a phase 3 trial of OPTI-201 for PTSD in 2027. The depression trial will enroll 200 adults with severe MDD. Participants will receive a single dose of naturally derived psilocybin or an active placebo. Both groups get identical psychological support and stop antidepressants before dosing.

The primary endpoint measures change in MADRS scores. The PTSD trial will test OPTI-201, a different psilocybin formulation, in a phase 3 design. These studies build on earlier phase 2 data showing rapid symptom reduction.

Can Psilocybin Replace Long-Term Antidepressants?

The timing reflects completed manufacturing scale-up and regulatory readiness. Opti Therapeutics has secured funding to support both trials simultaneously. The company emphasizes that psilocybin acts on serotonin receptors, offering a fast-acting alternative to traditional antidepressants. Clinical teams will monitor safety signals closely, given the drug's psychoactive profile.

The trials will answer whether a single dose can produce lasting remission. Researchers will track participants for 12 weeks post-dose. If results are positive, psilocybin could shift treatment paradigms from chronic medication to episodic intervention.

What is OPTI-101? OPTI-101 is a naturally derived psilocybin compound designed for depression treatment. It is administered as a single oral dose.

Frequently Asked Questions

How many patients are in the MDD trial? The phase 2b study plans to enroll 200 adults with severe major depressive disorder.

What is the primary outcome measure? The primary endpoint is the change in MADRS score from baseline to the 12-week follow-up visit.

More stories:

Share:

Leave a comment